Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway

Clinical Cancer Research

Volumn 17, Issue 7, 2011, Pages 1784-1795

  Boreddy, Srinivas Reddy ^a   Pramanik, Kartick C ^a   Srivastava, Sanjay K ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYL ISOTHIOCYANATE; BIM PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN 14 3 3; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; UPREGULATION;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CASPASE 3; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CREB-BINDING PROTEIN; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; I-KAPPA B KINASE; ISOTHIOCYANATES; MEMBRANE PROTEINS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; P300-CBP TRANSCRIPTION FACTORS; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIRTUINS; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

EID: 79953293746     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1891     Document Type: Article

References (45)

1. Li J, Wientjes MG, Au JL. Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J 2010;12:223-32.
2. Borja-Cacho D, Jensen EH, Saluja AK, Buchsbaum DJ, Vickers SM. Molecular targeted therapies for pancreatic cancer. Am J Surg 2008;196:430-41.
3. Fahy BN, Schlieman M, Virudachalam S, Bold RJ. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 2003;89:391-7. (Pubitemid 36976331)
4. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 30-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002;1:989-97.
5. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 2003;89:2110-5. (Pubitemid 38030911)
6. Gomes AR, Brosens JJ, Lam EW. Resist or die: FOXO transcription factors determine the cellular response to chemotherapy. Cell Cycle 2008;7:3133-6.
7. van Gorp AG, Pomeranz KM, Birkenkamp KU, Hui RC, Lam EW, Coffer PJ. Chronic protein kinase B (PKB/c-akt) activation leads to apoptosis induced by oxidative stress-mediated Foxo3a transcriptional up-regulation. Cancer Res 2006;66:10760-9. (Pubitemid 44876971)
8. Essafi A, Fernandez de Mattos S, Hassen YA, Soeiro I, Mufti GJ, Thomas NS, et al. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 2005;24:2317-29. (Pubitemid 40546691)
9. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 1992;18:1-29.
10. Bueno de Mesquita HB, Maisonneuve P, Runia S, Moerman CJ. Intake of foods and nutrients and cancer of the exocrine pancreas: a population-based case-control study in The Netherlands. Int J Cancer 1991;48:540-9.
11. Ji BT, Chow WH, Gridley G, McLaughlin JK, Dai Q, Wacholder S, et al. Dietary factors and the risk of pancreatic cancer: a case-control study in Shanghai China. Cancer Epidemiol Biomarkers Prev 1995;4:885-93.
12. Hecht SS. Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism. J Nutr 1999;129:768S-74S.
13. Stoner GD, Morse MA. Isothiocyanates and plant polyphenols as inhibitors of lung and esophageal cancer. Cancer Lett 1997;114:113-9. (Pubitemid 27140089)
14. Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci U S A 1992;89:2399-403.
15. Zhang R, Loganathan S, Humphreys I, Srivastava SK. Benzyl isothiocyanate-induced DNA damage causes G2/M cell cycle arrest and apoptosis in human pancreatic cancer cells. J Nutr 2006;136:2728-34. (Pubitemid 44771765)
16. Sahu RP, Srivastava SK. The role of STAT-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate. J Natl Cancer Inst 2009;101:176-93.
17. Sahu RP, Zhang R, Batra S, Shi Y, Srivastava SK. Benzyl isothiocyanate-mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of MAPK in human pancreatic cancer cells. Carcinogenesis 2009;30:1744-53.
18. Ji Y, Morris ME. Determination of phenethyl isothiocyanate in human plasma and urine by ammonia derivatization and liquid chromatography-tandem mass spectrometry. Anal Biochem 2003;323:39-47. (Pubitemid 37393356)
19. Batra S, Sahu RP, Kandala PK, Srivastava SK. Benzyl isothiocyanate- mediated inhibition of histone deacetylaseleads to NF-kappaB turn off in human pancreatic carcinoma cells. Mol Cancer Ther 2010;9:1596-608.
20. Sunters A, Madureira PA, Pomeranz KM, Aubert M, Brosens JJ, Cook SJ, et al. Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res 2006;66:212-20. (Pubitemid 43166027)
21. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001;20:6073-83. (Pubitemid 32955050)
22. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005;24: 7410-25. (Pubitemid 41637981)
23. Reagan-Shaw S, Ahmad N. The role of Forkhead-box Class O (FoxO) transcription factors in cancer: a target for the management of cancer. Toxicol Appl Pharmacol 2007;224:360-8. (Pubitemid 47575672)
24. Van Der Heide LP, Smidt MP. Regulation of FoxO activity by CBP/p300-mediated acetylation. Trends Biochem Sci 2005;30:81-6. (Pubitemid 40187300)
25. Kuiperij HB, Van Der Horst A, Raaijmakers J, Weijzen S, Medema RH, Bos JL, et al. Activation of FoxO transcription factors contributes to the antiproliferative effect of cAMP. Oncogene 2005;24:2087-95. (Pubitemid 40516202)
26. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501. (Pubitemid 37328931)
27. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002;5:234-48. (Pubitemid 36132805)
28. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332-7. (Pubitemid 38418805)
29. Gehrmann M, Schmidt M, Brase JC, Roos P, Hengstler JG. Prediction of paclitaxel resistance in breast cancer: is CYP1B1*3 a new factor of influence? Pharmacogenomics 2008;9:969-74.
30. Smith L, Watson MB, O'Kane SL, Drew PJ, Lind MJ, Cawkwell L. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther 2006;5:2115-20. (Pubitemid 44336583)
31. Sayaka Mori-Iwamoto YK, Shomei Ryozawa, Kumiko Taba, Masanori Fujimoto, Kiwamu Okita, Kazuyuki Nakamura, et al. A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines. Mol Med Rep 2008;1:6
32. Melinda M, Mortenson JMG, Michael G. Schlieman, Richard J. Bold. AKT: a novel target in pancreatic cancer therapy. Cancer Therapy. 2004;2:12.
33. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000;346:561-76. (Pubitemid 30171014)
34. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-45.
35. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004;9:667-76. (Pubitemid 40941196)
36. Sahu RP, Batra S, Srivastava SK. Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br J Cancer 2009;100:1425-33.
37. Lai KC, Huang AC, Hsu SC, Kuo CL, Yang JS, Wu SH, et al. Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. J Agric Food Chem 2010;58:2935-42.
38. Chow JY, Ban M, Wu HL, Nguyen F, Huang M, Chung H, et al. TGF-beta downregulates PTEN via activation of NF-kappaB in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol 2010;298:G275-82.
39. Teresi RE, Waite KA. PPARgamma, PTEN, and the fight against cancer. PPAR Res 2008;2008:1-6.
40. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serinethreonine kinase. Nature 1999;401:82-5.
41. Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 2010;95:819-28.
42. Bommareddy A, Hahm ER, Xiao D, Powolny AA, Fisher AL, Jiang Y, et al. Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells. Cancer Res 2009;69:3704-12.
43. Calnan DR, Brunet A. The FoxO code. Oncogene 2008;27:2276-88. (Pubitemid 351501779)
44. Dijkers PF, Birkenkamp KU, Lam EW, Thomas NS, Lammers JW, Koenderman L, et al. FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol 2002;156:531-42. (Pubitemid 34839900)
45. Frescas D, Valenti L, Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem 2005;280:20589-95. (Pubitemid 40776761)